Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

L Yu, J Wei, P Liu - Seminars in cancer biology, 2022 - Elsevier
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …

Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma

J Feng, J Li, L Wu, Q Yu, J Ji, J Wu, W Dai… - Journal of Experimental & …, 2020 - Springer
Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of
cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85 …

Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer

C Dong, J Wu, Y Chen, J Nie, C Chen - Frontiers in pharmacology, 2021 - frontiersin.org
Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …

Recent advances in targeted strategies for triple-negative breast cancer

S Zhu, Y Wu, B Song, M Yi, Y Yan, Q Mei… - Journal of Hematology & …, 2023 - Springer
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

[HTML][HTML] CCL5/CCR5 axis in human diseases and related treatments

Z Zeng, T Lan, Y Wei, X Wei - Genes & diseases, 2022 - Elsevier
To defense harmful stimuli or maintain the immune homeostasis, the body produces and
recruits a superfamily of cytokines such as interleukins, interferons, chemokines etc. Among …

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy

D Tewari, P Patni, A Bishayee, AN Sah… - Seminars in cancer …, 2022 - Elsevier
Abstract The phosphatidylinositol 3-kinase (PI3K)-Akt and the mammalian target of
rapamycin (mTOR) represent two vital intracellular signaling pathways, which are …

Targeted therapeutic options and future perspectives for HER2-positive breast cancer

J Wang, B Xu - Signal transduction and targeted therapy, 2019 - nature.com
Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Network pharmacology prediction and molecular docking-based strategy to discover the potential pharmacological mechanism of Huai Hua San against ulcerative …

J Liu, J Liu, X Tong, W Peng, S Wei, T Sun… - Drug Design …, 2021 - Taylor & Francis
Background Huai Hua San (HHS), a famous Traditional Chinese Medicine (TCM) formula,
has been widely applied in treating ulcerative colitis (UC). However, the interaction of …

AKT inhibitors: new weapons in the fight against breast cancer?

F Martorana, G Motta, G Pavone, L Motta… - Frontiers in …, 2021 - frontiersin.org
The serine/threonine kinase AKT is a key component of the PI3K/AKT/mTOR signaling
pathway as it exerts a pivotal role in cell growth, proliferation, survival, and metabolism …

Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR

MA Ortega, O Fraile-Martínez, Á Asúnsolo… - Journal of …, 2020 - Wiley Online Library
Breast cancer is the cancer with the highest prevalence in women and is the number‐one
cause of cancer mortality worldwide. Cell transduction is a fundamental process in the …